Biotage: Interim Report January - September 2006.

STOCKHOLM, Sweden -- Biotage (STO:BIOTA) Reports its best result ever:

* The company has been strongly aimed at the integration of previously acquired units with a focus on organic growth, gross margin and cost efficiency. For the third quarter Biotage reports its best result ever, with a positive operating result as well as a positive result after tax.

* Net sales increased by 6%in the third quarter and amounted to 133.9 MSEK (126.6 MSEK the previous year). In the period January - September 2006 net sales increased by 31% to 382.9 MSEK (292.0). The strong sales increase continues. At constant exchange rates and pro-forma* the increase was approx. 11% and in the first nine months approx. 10%.

* The operating result improved by 32.0 MSEK and amounted to 11.4 MSEK (-20.6). The operating result for the first nine months amounted to -2.9 MSEK (-58.3).

* The result after tax amounted to 8.6 MSEK (-27.6) and to -8.2 MSEK (-40.3) for the first nine months.

* Earnings per share amounted to 0.10 SEK (-0.39) and to -0.09 SEK (-0.61) in the first nine months.

* The cash flow from operating activities improved considerably and amounted to 17.4 MSEK (0.9) in the third quarter and to 11.9 MSEK (-31.9) in the first nine months.

* During the third quarter two package solutions in synthesis and purification were launched, targeting industry and academy, respectively. Biotage has already received the first orders according to the new program.

About Biotage

Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. In 2005 business and products from the company Argonaut were acquired, further strengthening the product range in medicinal chemistry. The customers include the world's top 30 pharma companies, the world's top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the U.S., Japan, UK, Germany and several other European countries. Biotage has 330 employees and had sales of 430 MSEK in 2005. Biotage is listed on the Stockholm stock exchange. Website: www.biotage.com

Note: Pro-forma refers to an adjustment for the distribution of Corbett's products in the Biosystems business area (divested in 2005), and for the Argonaut business in the Discovery Chemistry business area (acquired on June 3, 2005). The pro-forma figures have not been subject to review by the company's accountant.

This information was brought to you by Waymaker http://www.waymaker.net